Medtronic Ardian Luxembourg S.a.r.l.

Medtronic, Inc.

Gambro Uf Solutions, Inc.

Paul A Sobotka

Mark Gelfand

Howard Levin

Neil Chand Barman

Yong Kyun Cho

Douglas A Hettrick

Eduardo N Warman

Todd M Zielinski

John J O'Mahony

Vinod Sharma

Tom Dean Bennett

Edward G Rychlick

Charles P Sperling

Systems and methods include differential diagnosis for acute heart failure to provide treatment to a patient including determining whether the patient has cardiac volume overload, determining whether the patient has decreased abdominal venous system volume, and providing the appropriate treatment in response to the determinations. A multi-sensor system may be used to determine cardiac volume and abdominal venous system volume. Fluid redistribution treatment may be provided when cardiac volume overload is accompanied by a decrease in abdominal venous system volume. Fluid accumulation treatment may be provided when cardiac volume overload is not accompanied by a decrease in abdominal venous system volume.

Acute heart failure monitoring and treatment

Methods for treating dyspnea with therapeutic renal neuromodulation and associated system and methods are disclosed herein. One aspect of the present technology, for example, is directed to methods that block, reduce, and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry therapeutic benefits for patients with dyspnea.

Sympathetic state evaluation for renal neuromodulation therapy

Methods for treating polycystic kidney disease with therapeutic renal neuromodulation and associated systems and methods are disclosed herein. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate a renal artery of a kidney of a patient. One or more measurable physiological parameter corresponding to the polycystic kidney disease can thereby be reduced. Moreover, central sympathetic drive in the patient can be reduced in a manner that treats the patient for the polycystic kidney disease. Renal sympathetic nerve activity can be modulated along the afferent and/or efferent pathway. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a neuromodulation assembly, e.g., a neuromodulation assembly configured to cryotherapeutically cool the renal nerve or to deliver an energy field to the renal nerve.

Renal neuromodulation methods and devices for treatment of polycystic kidney disease

Methods for treating polycystic ovary syndrome with therapeutic ovarian neuromodulation and associated systems and methods are disclosed herein. Polycystic ovary syndrome can be associated, for example, with a condition including at least one of oligo/amenorrhea, infertility, hirsutism, obesity, metabolic syndrome, insulin resistance, and increased cardiovascular risk profile. One aspect of the present technology is directed to methods that at least partially inhibit sympathetic neural activity in nerves proximate an ovarian artery of an ovary of a patient. Sympathetic drive in the patient can thereby be reduced in a manner that treats the patient for the polycystic ovary syndrome. Ovarian sympathetic nerve activity can be modulated along afferent and/or efferent pathways. The modulation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the ovarian nerve.

Ovarian neuromodulation and associated systems and methods

Therapeutic renal neuromodulation for treating dyspnea and associated systems and methods

Methods for therapeutic renal denervation are disclosed herein. One aspect of the present application, for example, is directed to methods that block, reduce and/or inhibit renal sympathetic nerve activity to achieve a reduction in central sympathetic tone. Renal sympathetic nerve activity may be altered or modulated along the afferent and/or efferent pathway. The achieved reduction in central sympathetic tone may carry several therapeutic benefits across many disease states.

Methods for therapeutic renal denervation

A medical device and associated method for delivery of a cardiac therapy that includes determining a first impedance signal along a thoracic electrode vector extending within a portion of a thoracic cavity, determining a second impedance signal along an extra-thoracic electrode vector extending outside the thoracic cavity, comparing first amplitude measurements corresponding to the first impedance signals and second amplitude measurements corresponding to the second impedance signals, comparing first slope measurements corresponding to the first impedance signals and second slope measurements corresponding to the second impedance signals, and determining delivery of the cardiac therapy in response to the comparing.

Use of thoracic and extra-thoracic impedance for diagnostic monitoring

A blood volume control method has been developed including: monitoring a condition of a patient (such as hematocrit (Hct)), wherein the condition is indicative of blood volume in the patient; automatically determining that the condition indicates a low blood volume in the patient; automatically infusing an infusion solution into the patient in response to the determination of a low blood volume, and automatically adjusting the infusion to maintain the monitored condition at a predetermined value.

Growing community of inventors

West St. Paul, MN, United States of America

Paul A Sobotka